United Therapeutics Corporation (UTHR)
USD 293.65
(-4.46%)
USD 293.65
(-4.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.18 Billion USD | -5.26% |
| 2022 | 1.24 Billion USD | 3.11% |
| 2021 | 1.21 Billion USD | -0.79% |
| 2020 | 1.21 Billion USD | 7.66% |
| 2019 | 1.13 Billion USD | 85.01% |
| 2018 | 612.4 Million USD | -21.24% |
| 2017 | 777.6 Million USD | 67.8% |
| 2016 | 463.4 Million USD | -20.76% |
| 2015 | 584.79 Million USD | -5.5% |
| 2014 | 618.83 Million USD | -20.99% |
| 2013 | 783.25 Million USD | 47.3% |
| 2012 | 531.73 Million USD | -6.65% |
| 2011 | 569.59 Million USD | 3.99% |
| 2010 | 547.74 Million USD | 37.44% |
| 2009 | 398.53 Million USD | 9.6% |
| 2008 | 363.62 Million USD | 24.86% |
| 2007 | 291.22 Million USD | 6.31% |
| 2006 | 273.94 Million USD | 1579.5% |
| 2005 | 16.31 Million USD | 5.08% |
| 2004 | 15.52 Million USD | 32.25% |
| 2003 | 11.73 Million USD | -9.07% |
| 2002 | 12.9 Million USD | -17.9% |
| 2001 | 15.72 Million USD | -1.16% |
| 2000 | 15.9 Million USD | 152.5% |
| 1999 | 6.3 Million USD | 215.0% |
| 1998 | 2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.15 Billion USD | -2.12% |
| 2024 Q3 | 1.02 Billion USD | -0.37% |
| 2024 Q2 | 1.02 Billion USD | -11.33% |
| 2023 Q2 | 1.27 Billion USD | 3.88% |
| 2023 Q1 | 1.22 Billion USD | -2.0% |
| 2023 FY | 1.18 Billion USD | -5.26% |
| 2023 Q4 | 1.18 Billion USD | -9.86% |
| 2023 Q3 | 1.31 Billion USD | 3.24% |
| 2022 Q3 | 1.21 Billion USD | -0.45% |
| 2022 Q4 | 1.24 Billion USD | 2.33% |
| 2022 FY | 1.24 Billion USD | 3.11% |
| 2022 Q1 | 1.18 Billion USD | -2.21% |
| 2022 Q2 | 1.22 Billion USD | 3.5% |
| 2021 Q4 | 1.21 Billion USD | -0.74% |
| 2021 FY | 1.21 Billion USD | -0.79% |
| 2021 Q1 | 1.19 Billion USD | -1.98% |
| 2021 Q2 | 1.2 Billion USD | 0.82% |
| 2021 Q3 | 1.21 Billion USD | 1.14% |
| 2020 Q4 | 1.21 Billion USD | 8.13% |
| 2020 Q3 | 1.12 Billion USD | 0.21% |
| 2020 Q1 | 1.07 Billion USD | -4.91% |
| 2020 Q2 | 1.12 Billion USD | 4.48% |
| 2020 FY | 1.21 Billion USD | 7.66% |
| 2019 Q3 | 1.28 Billion USD | -3.63% |
| 2019 Q4 | 1.13 Billion USD | -11.75% |
| 2019 FY | 1.13 Billion USD | 85.01% |
| 2019 Q1 | 1.38 Billion USD | 126.73% |
| 2019 Q2 | 1.33 Billion USD | -4.06% |
| 2018 Q2 | 660.1 Million USD | 4.51% |
| 2018 Q1 | 631.6 Million USD | -18.78% |
| 2018 FY | 612.4 Million USD | -21.24% |
| 2018 Q4 | 612.4 Million USD | -12.53% |
| 2018 Q3 | 700.1 Million USD | 6.06% |
| 2017 Q2 | 896.2 Million USD | 84.75% |
| 2017 FY | 777.6 Million USD | 67.8% |
| 2017 Q1 | 485.1 Million USD | 4.68% |
| 2017 Q3 | 846.9 Million USD | -5.5% |
| 2017 Q4 | 777.6 Million USD | -8.18% |
| 2016 Q1 | 469.3 Million USD | -19.75% |
| 2016 FY | 463.4 Million USD | -20.76% |
| 2016 Q2 | 384.4 Million USD | -18.09% |
| 2016 Q3 | 419.6 Million USD | 9.16% |
| 2016 Q4 | 463.4 Million USD | 10.44% |
| 2015 Q4 | 584.79 Million USD | -13.98% |
| 2015 Q2 | 683.26 Million USD | -12.69% |
| 2015 Q1 | 782.56 Million USD | 26.46% |
| 2015 FY | 584.79 Million USD | -5.5% |
| 2015 Q3 | 679.86 Million USD | -0.5% |
| 2014 Q4 | 618.83 Million USD | -27.66% |
| 2014 Q3 | 855.49 Million USD | 15.64% |
| 2014 Q2 | 739.79 Million USD | -2.3% |
| 2014 Q1 | 757.24 Million USD | -3.32% |
| 2014 FY | 618.83 Million USD | -20.99% |
| 2013 Q3 | 619.54 Million USD | 10.33% |
| 2013 FY | 783.25 Million USD | 47.3% |
| 2013 Q4 | 783.25 Million USD | 26.43% |
| 2013 Q2 | 561.53 Million USD | 4.81% |
| 2013 Q1 | 535.76 Million USD | 0.76% |
| 2012 FY | 531.73 Million USD | -6.65% |
| 2012 Q3 | 586.66 Million USD | 7.29% |
| 2012 Q1 | 536.78 Million USD | -5.76% |
| 2012 Q4 | 531.73 Million USD | -9.36% |
| 2012 Q2 | 546.8 Million USD | 1.87% |
| 2011 Q1 | 561.19 Million USD | 2.45% |
| 2011 FY | 569.59 Million USD | 3.99% |
| 2011 Q4 | 569.59 Million USD | -2.15% |
| 2011 Q3 | 582.08 Million USD | 0.99% |
| 2011 Q2 | 576.39 Million USD | 2.71% |
| 2010 FY | 547.74 Million USD | 37.44% |
| 2010 Q1 | 398.45 Million USD | -0.02% |
| 2010 Q4 | 547.74 Million USD | 23.91% |
| 2010 Q3 | 442.05 Million USD | 9.05% |
| 2010 Q2 | 405.37 Million USD | 1.74% |
| 2009 Q1 | 325.53 Million USD | -10.47% |
| 2009 FY | 398.53 Million USD | 9.6% |
| 2009 Q4 | 398.53 Million USD | 9.14% |
| 2009 Q3 | 365.17 Million USD | 5.33% |
| 2009 Q2 | 346.69 Million USD | 6.5% |
| 2008 Q4 | 363.62 Million USD | 4.46% |
| 2008 FY | 363.62 Million USD | 24.86% |
| 2008 Q1 | 311.63 Million USD | 7.01% |
| 2008 Q2 | 305.52 Million USD | -1.96% |
| 2008 Q3 | 348.09 Million USD | 13.93% |
| 2007 Q1 | 273.91 Million USD | -0.01% |
| 2007 Q4 | 291.22 Million USD | -3.62% |
| 2007 Q2 | 292.79 Million USD | 6.89% |
| 2007 FY | 291.22 Million USD | 6.31% |
| 2007 Q3 | 302.17 Million USD | 3.2% |
| 2006 FY | 273.94 Million USD | 1579.5% |
| 2006 Q4 | 273.94 Million USD | 1105.32% |
| 2006 Q3 | 22.72 Million USD | -12.29% |
| 2006 Q2 | 25.91 Million USD | 33.13% |
| 2006 Q1 | 19.46 Million USD | 19.34% |
| 2005 Q1 | 13.61 Million USD | -12.29% |
| 2005 Q2 | 17.42 Million USD | 27.99% |
| 2005 Q3 | 18.81 Million USD | 7.98% |
| 2005 Q4 | 16.31 Million USD | -13.31% |
| 2005 FY | 16.31 Million USD | 5.08% |
| 2004 Q1 | 10.98 Million USD | -6.4% |
| 2004 FY | 15.52 Million USD | 32.25% |
| 2004 Q4 | 15.52 Million USD | -1.58% |
| 2004 Q3 | 15.77 Million USD | 24.52% |
| 2004 Q2 | 12.66 Million USD | 15.28% |
| 2003 Q2 | 15.2 Million USD | 11.22% |
| 2003 FY | 11.73 Million USD | -9.07% |
| 2003 Q3 | 18.53 Million USD | 21.93% |
| 2003 Q4 | 11.73 Million USD | -36.68% |
| 2003 Q1 | 13.66 Million USD | 5.9% |
| 2002 Q2 | 14.56 Million USD | 27.83% |
| 2002 Q1 | 11.39 Million USD | -27.52% |
| 2002 Q3 | 13.36 Million USD | -8.26% |
| 2002 Q4 | 12.9 Million USD | -3.41% |
| 2002 FY | 12.9 Million USD | -17.9% |
| 2001 Q4 | 15.72 Million USD | 8.39% |
| 2001 Q3 | 14.5 Million USD | -10.72% |
| 2001 FY | 15.72 Million USD | -1.16% |
| 2001 Q1 | 16.2 Million USD | 1.89% |
| 2001 Q2 | 16.24 Million USD | 0.24% |
| 2000 Q1 | 6.82 Million USD | 8.28% |
| 2000 FY | 15.9 Million USD | 152.5% |
| 2000 Q3 | 9.66 Million USD | 12.92% |
| 2000 Q4 | 15.9 Million USD | 64.54% |
| 2000 Q2 | 8.56 Million USD | 25.5% |
| 1999 Q2 | 1.6 Million USD | -30.43% |
| 1999 Q4 | 6.3 Million USD | 53.66% |
| 1999 FY | 6.3 Million USD | 215.0% |
| 1999 Q3 | 4.1 Million USD | 156.25% |
| 1999 Q1 | 2.3 Million USD | 0.0% |
| 1998 FY | 2 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | -252.08% |
| Alkermes plc | 933.53 Million USD | -26.637% |
| Agenus Inc. | 462.29 Million USD | -155.724% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 70.814% |
| Aptorum Group Limited | 5.25 Million USD | -22389.232% |
| Ardelyx, Inc. | 130.76 Million USD | -804.078% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | -147.121% |
| Bicycle Therapeutics plc | 224.41 Million USD | -426.799% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -807.918% |
| ChromaDex Corporation | 26.5 Million USD | -4359.786% |
| Chimerix, Inc. | 19.74 Million USD | -5887.339% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -3260.708% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -1529.115% |
| CRISPR Therapeutics AG | 346.76 Million USD | -240.92% |
| Precision BioSciences, Inc. | 140.92 Million USD | -738.916% |
| Dyadic International, Inc. | 2.34 Million USD | -50407.316% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -7169.262% |
| Fortress Biotech, Inc. | 165.93 Million USD | -612.43% |
| Lantern Pharma Inc. | 2.73 Million USD | -43050.993% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -1553.889% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -33402.186% |
| Incyte Corporation | 1.59 Billion USD | 25.754% |
| IO Biotech, Inc. | 17.55 Million USD | -6633.88% |
| Jaguar Health, Inc. | 45.86 Million USD | -2477.508% |
| Novavax, Inc. | 2.57 Billion USD | 54.041% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -3178.607% |
| Opthea Limited | 264.6 Million USD | -346.785% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -804.466% |
| ContextLogic Inc. | 206 Million USD | -473.883% |
| MiMedx Group, Inc. | 96.33 Million USD | -1127.24% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -2361.788% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -33400.648% |
| NextCure, Inc. | 14.99 Million USD | -7782.91% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -29147.897% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -17605.556% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -2429.365% |
| Vaxcyte, Inc. | 167.44 Million USD | -606.006% |
| PDS Biotechnology Corporation | 33.25 Million USD | -3454.512% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -402.606% |
| Pharming Group N.V. | 244.07 Million USD | -384.363% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -9816.121% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -825.104% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -17792.388% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -17792.388% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1334.134% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -17696.176% |
| Acelyrin, Inc. | 86.35 Million USD | -1269.032% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -90891.587% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -8121.712% |
| Summit Therapeutics Inc. | 125.25 Million USD | -843.82% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -12371.78% |
| Senti Biosciences, Inc. | 52.57 Million USD | -2148.768% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -1618.889% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -680.268% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -60339.673% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -88416.911% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -421.179% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -12520.903% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -419.774% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | -139.065% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -10731.959% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -4197.19% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -9666.455% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | -142.951% |
| Immix Biopharma, Inc. | 3.72 Million USD | -31664.345% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -3026.521% |
| MEI Pharma, Inc. | 8.35 Million USD | -14049.611% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -3974.444% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -240.123% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -710.453% |
| Fortress Biotech, Inc. | 165.93 Million USD | -612.43% |
| Precigen, Inc. | 41.64 Million USD | -2738.824% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -2267.715% |
| AlloVir, Inc. | 45.01 Million USD | -2526.236% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -807.033% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -757.91% |
| ImmuCell Corporation | 18.81 Million USD | -6183.276% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -4088.337% |
| Onconetix, Inc. | 23.18 Million USD | -4999.891% |
| PureTech Health plc | 125.58 Million USD | -841.369% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -13108.939% |
| Elevation Oncology, Inc. | 34.28 Million USD | -3348.457% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -48251.738% |
| Seer, Inc. | 39.36 Million USD | -2903.175% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -1811.893% |
| Innoviva, Inc. | 568.55 Million USD | -107.932% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -4241.854% |
| ESSA Pharma Inc. | 3.49 Million USD | -33724.778% |
| GlycoMimetics, Inc. | 6.9 Million USD | -17028.185% |
| GT Biopharma, Inc. | 6.63 Million USD | -17723.006% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -347.142% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -334.174% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -1306.945% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -11995.355% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -4251.283% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -36548.58% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -1502.614% |
| Aptose Biosciences Inc. | 15.8 Million USD | -7378.16% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -10608.638% |
| Soligenix, Inc. | 7.27 Million USD | -16150.386% |
| Century Therapeutics, Inc. | 175.94 Million USD | -571.93% |
| Kura Oncology, Inc. | 51.66 Million USD | -2188.336% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -874.753% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -28503.92% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -17774.598% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -368.016% |
| Autolus Therapeutics plc | 263.9 Million USD | -347.961% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -11178.382% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -1230.392% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -2420.736% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -235.038% |
| GRI Bio, Inc. | 2.69 Million USD | -43733.89% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -145925.433% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -3702.387% |
| IGM Biosciences, Inc. | 220.17 Million USD | -436.932% |
| INmune Bio, Inc. | 18.86 Million USD | -6167.628% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -360.934% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -4337.386% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -43388.721% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -35939.76% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -1922.41% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -1129.422% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -346.56% |
| Coherus BioSciences, Inc. | 823.02 Million USD | -43.64% |
| Verastem, Inc. | 71.18 Million USD | -1560.743% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -2304.018% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -2964.441% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -2316.006% |
| Histogen Inc. | 5.69 Million USD | -20651.273% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -26856.372% |
| Surrozen, Inc. | 8.14 Million USD | -14414.426% |
| Organovo Holdings, Inc. | 2.74 Million USD | -42920.378% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -376567.155% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -2002.44% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -7059.641% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -2213.367% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -142872.033% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -832.886% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -10832.54% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -683.49% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -45241.142% |
| Apollomics, Inc. | 14.15 Million USD | -8252.999% |
| Amarin Corporation plc | 279.58 Million USD | -322.838% |
| Mesoblast Limited | 188.79 Million USD | -526.172% |
| Turnstone Biologics Corp. | 14.14 Million USD | -8255.951% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -553.915% |
| Synaptogenix, Inc. | 5.52 Million USD | -21279.991% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -17682.792% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -594.97% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -13715.278% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -67170.098% |
| Exelixis, Inc. | 678.44 Million USD | -74.251% |
| Better Therapeutics, Inc. | 23.84 Million USD | -4858.477% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -620.652% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | -98.954% |
| NLS Pharmaceutics AG | 10.68 Million USD | -10969.077% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -72712.783% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -2936.967% |
| Gritstone bio, Inc. | 125.91 Million USD | -838.858% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -7955.328% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -23132.2% |
| Avid Bioservices, Inc. | 275.66 Million USD | -328.849% |
| Insmed Incorporated | 1.66 Billion USD | 28.859% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -15265.172% |
| MediWound Ltd. | 27.18 Million USD | -4248.402% |
| OmniAb, Inc. | 87.4 Million USD | -1252.632% |
| Alector, Inc. | 487.66 Million USD | -142.419% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -193.018% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -6316.282% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -2980.812% |
| Zai Lab Limited | 240.17 Million USD | -392.22% |
| Revance Therapeutics, Inc. | 630.05 Million USD | -87.634% |
| Aura Biosciences, Inc. | 29.22 Million USD | -3944.89% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -1143.413% |
| Immunic, Inc. | 25.36 Million USD | -4560.202% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -1607.493% |
| Veracyte, Inc. | 93.71 Million USD | -1161.43% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -45079.508% |
| FibroGen, Inc. | 585.72 Million USD | -101.834% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -6700.897% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -180920.279% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -20803.7% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 84.559% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -14320.59% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -1307.012% |
| TG Therapeutics, Inc. | 169.08 Million USD | -599.175% |
| Galecto, Inc. | 5.89 Million USD | -19950.882% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -14170.884% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 54.85% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -4001.728% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -9266.928% |
| XBiotech Inc. | 8.39 Million USD | -13978.838% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -7955.328% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -2123.016% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -225.58% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -4297.411% |
| Theravance Biopharma, Inc. | 169 Million USD | -599.51% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 2.748% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | -136.239% |
| Vaxxinity, Inc. | 30.94 Million USD | -3720.45% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | -21.564% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -19501.708% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | -58.635% |
| NexImmune, Inc. | 5.08 Million USD | -23152.283% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -318214.243% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -38347.429% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 83.366% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -22837.391% |
| Scopus BioPharma Inc. | 7.45 Million USD | -15759.018% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -4396.083% |
| Ainos, Inc. | 7.39 Million USD | -15888.157% |
| Pluri Inc. | 34.11 Million USD | -3365.643% |
| Prothena Corporation plc | 135.01 Million USD | -775.593% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -386.296% |
| Celularity Inc. | 102.92 Million USD | -1048.559% |
| Rallybio Corporation | 9.43 Million USD | -12428.614% |
| Cue Biopharma, Inc. | 24.44 Million USD | -4736.163% |
| MeiraGTx Holdings plc | 319.99 Million USD | -269.448% |
| Omeros Corporation | 403.25 Million USD | -193.167% |
| Humacyte, Inc. | 114.67 Million USD | -930.895% |
| Immunocore Holdings plc | 228.15 Million USD | -418.15% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -24150.256% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -1440.526% |
| Blueprint Medicines Corporation | 918.64 Million USD | -28.69% |
| CalciMedica, Inc. | 4.02 Million USD | -29249.553% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -6674.009% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -666.95% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -1277.583% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -325.569% |
| Pulmatrix, Inc. | 15.96 Million USD | -7305.876% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -7395.087% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -4704.519% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -371.357% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -2227.806% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 2.349% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -3619.599% |
| Nutriband Inc. | 1.07 Million USD | -109472.637% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -11018.217% |
| Vor Biopharma Inc. | 59.1 Million USD | -1900.203% |
| Roivant Sciences Ltd. | 773.95 Million USD | -52.748% |
| Evogene Ltd. | 17.99 Million USD | -6471.429% |
| ProKidney Corp. | 29.21 Million USD | -3946.413% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -1542.423% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -167591.987% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 37.414% |
| CorMedix Inc. | 11.91 Million USD | -9819.842% |
| BioLineRx Ltd. | 50.7 Million USD | -2231.663% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -690.986% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -1236.71% |
| Atai Life Sciences N.V. | 49.16 Million USD | -2304.703% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -3694.904% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -6481.672% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -848.522% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -20809.091% |
| MediciNova, Inc. | 3.89 Million USD | -30278.617% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -6367.531% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -78491.13% |
| GeoVax Labs, Inc. | 3.51 Million USD | -33486.363% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -197.589% |
| Biomea Fusion, Inc. | 30.69 Million USD | -3752.069% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 56.564% |
| Mereo BioPharma Group plc | 15.96 Million USD | -7306.34% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -3688.981% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -1914.518% |
| Absci Corporation | 58.3 Million USD | -1927.648% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -6106.426% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -3587.231% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -1502.114% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -1251.348% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -3400.74% |
| Allakos Inc. | 74.79 Million USD | -1480.629% |
| Imunon, Inc. | 8.53 Million USD | -13758.626% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -5153.989% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -929.683% |
| BioAtla, Inc. | 48.98 Million USD | -2313.343% |
| NLS Pharmaceutics AG | 10.68 Million USD | -10969.077% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -42440.482% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -805.179% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -8216.567% |
| XOMA Corporation | 145.58 Million USD | -712.062% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -3411.659% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -1619.339% |
| aTyr Pharma, Inc. | 31.59 Million USD | -3641.494% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -1812.233% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -2529.156% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -2342.461% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -41091.638% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -14391.265% |
| Akari Therapeutics, Plc | 4.58 Million USD | -25689.703% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -6566.618% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 28.328% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -292590.415% |
| UroGen Pharma Ltd. | 243.52 Million USD | -385.457% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -268.187% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -42709.168% |
| Orgenesis Inc. | 35.53 Million USD | -3226.861% |
| Entera Bio Ltd. | 1.37 Million USD | -85628.789% |
| GH Research PLC | 6.7 Million USD | -17542.143% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -17285.294% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -6179.613% |
| Xencor, Inc. | 283.55 Million USD | -316.915% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -39495.736% |
| Replimune Group, Inc. | 113.21 Million USD | -944.217% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -31365.549% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -1041.891% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -292590.415% |
| Portage Biotech Inc. | 4.45 Million USD | -26466.292% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -78491.13% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -5028.85% |
| OncoCyte Corporation | 49.29 Million USD | -2298.069% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -28477.61% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -148141.219% |
| Purple Biotech Ltd. | 10 Million USD | -11716.092% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -20332.077% |
| scPharmaceuticals Inc. | 57.26 Million USD | -1964.581% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -9443.09% |
| HilleVax, Inc. | 78.9 Million USD | -1398.181% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -23309.901% |
| Tharimmune, Inc. | 1.81 Million USD | -65033.335% |
| Genprex, Inc. | 3.25 Million USD | -36228.348% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -4259.305% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -22478.304% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -573783.495% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -329618.755% |
| OKYO Pharma Limited | 7.42 Million USD | -15830.798% |
| Savara Inc. | 37.19 Million USD | -3078.641% |
| Curis, Inc. | 57.61 Million USD | -1952.003% |
| Daré Bioscience, Inc. | 26.32 Million USD | -4389.96% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -2915.832% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -81769.806% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -5578.467% |
| BeiGene, Ltd. | 2.23 Billion USD | 47.075% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -5452.894% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -350.539% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -5457.018% |
| Erasca, Inc. | 78.61 Million USD | -1403.861% |
| bluebird bio, Inc. | 424.62 Million USD | -178.411% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -180319.136% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 37.452% |
| DBV Technologies S.A. | 42.8 Million USD | -2662.15% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -180319.136% |
| Moderna, Inc. | 4.57 Billion USD | 74.143% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -16800.643% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -71288.889% |
| Molecular Templates, Inc. | 31.17 Million USD | -3692.628% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -6825.6% |
| Travere Therapeutics, Inc. | 588.1 Million USD | -101.019% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -849.52% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -4208.78% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -3142.813% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -2024.921% |
| MacroGenics, Inc. | 154.2 Million USD | -666.632% |
| RenovoRx, Inc. | 4.46 Million USD | -26371.115% |
| Adicet Bio, Inc. | 37.12 Million USD | -3084.806% |
| Prime Medicine, Inc. | 60.78 Million USD | -1845.048% |
| Aditxt, Inc. | 28.53 Million USD | -4043.482% |
| Adagene Inc. | 45.16 Million USD | -2517.262% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -654129.916% |
| Quantum-Si incorporated | 26.63 Million USD | -4339.187% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | -69.475% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -38756.996% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -928.349% |
| SciSparc Ltd. | 1.59 Million USD | -74019.122% |
| Vericel Corporation | 127.7 Million USD | -825.727% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -21143.891% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -1284.989% |
| Generation Bio Co. | 171.63 Million USD | -588.807% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -10135.498% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -2726.134% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -367.831% |
| Invivyd, Inc. | 51.71 Million USD | -2186.079% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -1185.321% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -18073.011% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -1465.911% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -115688.443% |
| 2seventy bio, Inc. | 310.12 Million USD | -281.2% |
| ADMA Biologics, Inc. | 193.97 Million USD | -509.457% |
| Clene Inc. | 38.95 Million USD | -2935.095% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -3171.814% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -360.043% |
| GeoVax Labs, Inc. | 3.51 Million USD | -33486.363% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -521.35% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -9606.345% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -496.101% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -9594.296% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -2357.234% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -2137.278% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -219.64% |
| Evaxion Biotech A/S | 17.61 Million USD | -6610.381% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -634.61% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -671.742% |
| Trevena, Inc. | 48.26 Million USD | -2349.546% |
| Surrozen, Inc. | 8.14 Million USD | -14414.426% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -5374.415% |
| Cingulate Inc. | 10.36 Million USD | -11310.244% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -42889.091% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -3070.117% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -32862.314% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -8890.114% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -272.697% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -4657.536% |
| Clearmind Medicine Inc. | 3.61 Million USD | -32647.85% |
| Kronos Bio, Inc. | 54.2 Million USD | -2081.141% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -2413.02% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -5094.262% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -5790.09% |
| Statera Biopharma, Inc. | 22.67 Million USD | -5113.337% |
| ImmunityBio, Inc. | 1.09 Billion USD | -8.42% |
| Korro Bio, Inc. | 51.75 Million USD | -2184.356% |
| Kineta, Inc. | 7.22 Million USD | -16269.427% |
| BioVie Inc. | 9.7 Million USD | -12084.953% |
| Codexis, Inc. | 49.94 Million USD | -2266.956% |
| Celularity Inc. | 102.92 Million USD | -1048.559% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -1128.298% |
| Celcuity Inc. | 51.45 Million USD | -2197.761% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -342374.087% |
| Cibus, Inc. | 206.11 Million USD | -473.558% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -2683.284% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -4388.401% |
| IN8bio, Inc. | 8.77 Million USD | -13376.972% |
| Kodiak Sciences Inc. | 213.59 Million USD | -453.488% |
| Annexon, Inc. | 47.11 Million USD | -2409.02% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -1220.289% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -1126.705% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -8536.131% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 54.59% |
| Eyenovia, Inc. | 19.78 Million USD | -5876.66% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -567.585% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -15291.225% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -4805.598% |
| Arcellx, Inc. | 339.75 Million USD | -247.96% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -9836.124% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -381.469% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -12262.229% |
| Moolec Science SA | 13.94 Million USD | -8377.374% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -2639.618% |
| Geron Corporation | 146.12 Million USD | -709.022% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -2239.508% |
| Royalty Pharma plc | 6.29 Billion USD | 81.228% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -2872.144% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -401454.316% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -47951.402% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -524.987% |
| Humacyte, Inc. | 114.67 Million USD | -930.895% |
| Structure Therapeutics Inc. | 29.05 Million USD | -3969.395% |
| 89bio, Inc. | 59.96 Million USD | -1871.549% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -4367.37% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -98746.154% |
| Genelux Corporation | 8.42 Million USD | -13940.38% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -17143.291% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -767.231% |
| Notable Labs, Ltd. | 4.42 Million USD | -26604.314% |
| Liquidia Corporation | 73.13 Million USD | -1516.396% |
| Mustang Bio, Inc. | 17.61 Million USD | -6609.802% |
| Immunovant, Inc. | 48.95 Million USD | -2314.871% |
| Quantum-Si incorporated | 26.63 Million USD | -4339.187% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -2980.009% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -37998.614% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -1500.574% |
| Acasti Pharma Inc. | 11.55 Million USD | -10129.298% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -5129.185% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -43388.721% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -3105.792% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -86645.199% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -19293.045% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -4660.217% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -4999.206% |
| PepGen Inc. | 34.63 Million USD | -3313.704% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -9634.848% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -16827.262% |
| Solid Biosciences Inc. | 38.45 Million USD | -2974.003% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -13715.278% |
| Immuneering Corporation | 12 Million USD | -9744.812% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -376567.155% |
| Silo Pharma, Inc. | 1.56 Million USD | -75234.391% |
| Belite Bio, Inc | 4.21 Million USD | -27974.092% |
| XOMA Corporation | 145.58 Million USD | -712.062% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -48590.28% |
| Bionomics Limited | 10.15 Million USD | -11537.292% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -5400.907% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -5059.516% |
| uniQure N.V. | 624.01 Million USD | -89.449% |
| Cassava Sciences, Inc. | 14.19 Million USD | -8228.285% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -654129.916% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -594.66% |
| Forte Biosciences, Inc. | 3.66 Million USD | -32147.681% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -453575.029% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -17421.862% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -15291.225% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -6700.897% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -11086.601% |
| Altimmune, Inc. | 16.54 Million USD | -7047.089% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -91.386% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -5059.516% |
| Compugen Ltd. | 55.77 Million USD | -2019.588% |
| Peak Bio, Inc. | 20.75 Million USD | -5596.426% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -970.223% |
| Benitec Biopharma Inc. | 4.96 Million USD | -23725.071% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -648.972% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -1472.618% |
| Zura Bio Limited | 21.29 Million USD | -5452.32% |
| PolyPid Ltd. | 17.46 Million USD | -6667.804% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -951.789% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -1472.618% |
| Instil Bio, Inc. | 99.8 Million USD | -1084.557% |
| argenx SE | 444.95 Million USD | -165.692% |
| Immunome, Inc. | 28.65 Million USD | -4025.201% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -14080.161% |
| Verona Pharma plc | 58.84 Million USD | -1909.143% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -8068.313% |
| Shattuck Labs, Inc. | 14.85 Million USD | -7856.121% |
| CervoMed Inc. | 2.59 Million USD | -45443.73% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -24155.232% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -9182.349% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -11121.642% |
| Moolec Science SA | 13.94 Million USD | -8377.374% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -50345.828% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -2026.439% |
| AnaptysBio, Inc. | 364.28 Million USD | -224.525% |
| Design Therapeutics, Inc. | 11.95 Million USD | -9787.922% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -9220.404% |
| NeurAxis, Inc. | 1.91 Million USD | -61706.655% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -2936.889% |
| Lumos Pharma, Inc. | 13.33 Million USD | -8766.722% |
| Achilles Therapeutics plc | 19.08 Million USD | -6093.744% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -8068.313% |
| 180 Life Sciences Corp. | 5.38 Million USD | -21844.573% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -4911.873% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -5094.262% |
| Nutriband Inc. | 1.07 Million USD | -109472.637% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -3763.651% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -8046.923% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -194.612% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -3540.563% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -8959.631% |
| Palisade Bio, Inc. | 2.73 Million USD | -43061.738% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -22405.235% |
| Beam Therapeutics Inc. | 478.38 Million USD | -147.123% |
| Neurogene Inc. | 36.54 Million USD | -3134.562% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -197.072% |
| AEON Biopharma, Inc. | 159.88 Million USD | -639.388% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -2381.007% |
| Sesen Bio, Inc. | 30.98 Million USD | -3715.518% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -4453.754% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -15450.729% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -503.971% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -515.546% |
| Athira Pharma, Inc. | 30.05 Million USD | -3833.194% |
| Vaccinex, Inc. | 5.94 Million USD | -19795.658% |
| HCW Biologics Inc. | 15.05 Million USD | -7754.136% |
| XOMA Corporation | 145.58 Million USD | -712.062% |
| Nektar Therapeutics | 267.04 Million USD | -342.695% |
| Arvinas, Inc. | 644.6 Million USD | -83.401% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -6566.618% |
| Merus N.V. | 102.15 Million USD | -1057.306% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -707.79% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -1142.851% |
| Rezolute, Inc. | 11.73 Million USD | -9974.996% |
| Clene Inc. | 38.95 Million USD | -2935.095% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -41418.87% |
| BeyondSpring Inc. | 48.26 Million USD | -2349.191% |
| Synlogic, Inc. | 32.89 Million USD | -3493.859% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -7990.057% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -72250.061% |
| Peak Bio, Inc. | 20.75 Million USD | -5596.426% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -1762.935% |
| Krystal Biotech, Inc. | 39.71 Million USD | -2876.784% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -213.877% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -1087.317% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -273098.283% |
| MannKind Corporation | 721.36 Million USD | -63.884% |
| Ikena Oncology, Inc. | 22.33 Million USD | -5193.038% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -56573.058% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -1052.354% |
| Gossamer Bio, Inc. | 249.14 Million USD | -374.499% |
| CohBar, Inc. | 1.03 Million USD | -114272.73% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -10959.968% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -6106.426% |
| Legend Biotech Corporation | 589.93 Million USD | -100.396% |
| Mural Oncology plc | 37.92 Million USD | -3016.958% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -791.312% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -51404.532% |
| Disc Medicine, Inc. | 22.87 Million USD | -5068.087% |
| Champions Oncology, Inc. | 28.03 Million USD | -4116.872% |
| REGENXBIO Inc. | 262.22 Million USD | -350.829% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -35091.311% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -9331.945% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -8701.614% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -5475.1% |
| Vaxart, Inc. | 34.02 Million USD | -3374.504% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -5698.149% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -4043.435% |
| Cellectis S.A. | 249.57 Million USD | -373.685% |
| Longeveron Inc. | 5.33 Million USD | -22051.021% |
| Repare Therapeutics Inc. | 41.81 Million USD | -2726.945% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 50.849% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -1858.322% |
| Revolution Medicines, Inc. | 262.39 Million USD | -350.539% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -56008.211% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -13605.078% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -9917.795% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -8318.429% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -54860.483% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 77.044% |
| Denali Therapeutics Inc. | 122.96 Million USD | -861.427% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -21143.891% |
| Veru Inc. | 32.81 Million USD | -3502.873% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -17110.657% |
| Cingulate Inc. | 10.36 Million USD | -11310.244% |
| Passage Bio, Inc. | 39.26 Million USD | -2911.054% |
| Context Therapeutics Inc. | 4.19 Million USD | -28103.253% |
| Exicure, Inc. | 8.54 Million USD | -13728.518% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -3906.371% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -11174.08% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -5263.64% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -625.338% |
| Nuvalent, Inc. | 31.82 Million USD | -3614.923% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -18483.296% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -1775.853% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -6467.778% |
| OmniAb, Inc. | 87.4 Million USD | -1252.632% |
| Anew Medical, Inc. | 8.24 Million USD | -14243.956% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -2987.563% |
| Lipocine Inc. | 2.63 Million USD | -44822.746% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -4399.848% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -2839.918% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -4337.386% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -1272.194% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -21788.539% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -1328.692% |
| Ocugen, Inc. | 23.98 Million USD | -4829.325% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -2447.461% |
| Q32 Bio Inc. | 233.12 Million USD | -407.103% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -12939.929% |
| Alumis Inc. Common Stock | 53.5 Million USD | -2109.637% |
| Equillium, Inc. | 27.95 Million USD | -4128.637% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -472.239% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -20910.67% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -19176.148% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -651.433% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -1602.649% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -11752.578% |
| Dominari Holdings Inc. | 4.63 Million USD | -25405.933% |
| Edesa Biotech, Inc. | 1.84 Million USD | -64092.889% |
| vTv Therapeutics Inc. | 29.56 Million USD | -3898.377% |
| Bio-Techne Corporation | 744.34 Million USD | -58.825% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -837.517% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -243.208% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -2813.617% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -3982.605% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -1179.991% |
| Nkarta, Inc. | 105.6 Million USD | -1019.508% |
| BioCardia, Inc. | 4.59 Million USD | -25655.991% |
| Iterum Therapeutics plc | 32.66 Million USD | -3519.497% |